Clinical Trial Update: YAZ Premenstrual Dysphoric Disorder (PMDD) in China [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating YAZ (drospirenone/ethinyl estradiol) for Premenstrual Dysphoric Disorder in China has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premenstrual Dysphoric Disorder

Drugs mentioned

• YAZ (DROSPIRENONE AND ETHINYL ESTRADIOL)

Snippet

Sponsor: Bayer | Conditions: Premenstrual Dysphoric Disorder ( PMDD) | Phase 3 | Status: COMPLETED